Skip to content
ChickenStockChickenStock
ResearchIOVA
Iovance Biotherapeutics logo

Iovance Biotherapeutics (IOVA) stock

NASDAQ

$7.53-0.26%(-0.02)

As of the Nov 17, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-15.85x

Net loss — not comparable

P/B

4.29x

P/S

9.20x

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue increased 80.6% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 5, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

22 SEC filings
  • Vogt Frederick GInterim CEO & General Counsel · Nov 11, 2026Shares withheld for taxes191,303 shares · $1.5M
    Avg. price $8.09604,144 shares held after
  • Vogt Frederick GInterim CEO & General Counsel · Nov 11, 2026Option exercise200,000 shares · $1.5M
    Avg. price $7.55795,447 shares held after
  • Kirby Daniel GordonChief Commercial Officer · Nov 10, 2026Shares withheld for taxes3,935 shares · $32K
    Avg. price $8.08160,576 shares held after
  • Kirby Daniel GordonChief Commercial Officer · Nov 10, 2026Option exercise10,000 shares · $0
    Avg. price $0164,511 shares held after
  • Roche Corleen M.Chief Financial Officer · Nov 6, 2026Shares withheld for taxes5,311 shares · $43K
    Avg. price $8.0435,946 shares held after
  • Roche Corleen M.Chief Financial Officer · Nov 6, 2026Option exercise12,500 shares · $0
    Avg. price $041,257 shares held after
  • Vogt Frederick GInterim CEO & General Counsel · Sep 8, 2026Shares withheld for taxes6,638 shares · $58K
    Avg. price $8.7595,447 shares held after
  • Puri Raj K.Chief Regulatory Officer · Sep 8, 2026Shares withheld for taxes4,478 shares · $39K
    Avg. price $8.7256,364 shares held after
  • BILINSKY IGORChief Operating Officer · Sep 8, 2026Shares withheld for taxes3,976 shares · $35K
    Avg. price $8.7142,074 shares held after
  • BILINSKY IGORChief Operating Officer · Sep 8, 2026Option exercise7,813 shares · $0
    Avg. price $0146,050 shares held after
  • Puri Raj K.Chief Regulatory Officer · Sep 8, 2026Option exercise9,766 shares · $0
    Avg. price $0260,842 shares held after
  • Vogt Frederick GInterim CEO & General Counsel · Sep 8, 2026Option exercise15,626 shares · $0
    Avg. price $0602,085 shares held after
  • Vogt Frederick GInterim CEO & General Counsel · Sep 1, 2026Shares withheld for taxes17,702 shares · $147K
    Avg. price $8.28586,459 shares held after
  • BILINSKY IGORChief Operating Officer · Sep 1, 2026Shares withheld for taxes4,472 shares · $37K
    Avg. price $8.28138,237 shares held after
  • Puri Raj K.Chief Regulatory Officer · Sep 1, 2026Shares withheld for taxes2,508 shares · $21K
    Avg. price $8.28251,076 shares held after
  • BILINSKY IGORChief Operating Officer · Sep 1, 2026Option exercise8,789 shares · $0
    Avg. price $0142,709 shares held after
  • Vogt Frederick GInterim CEO & General Counsel · Sep 1, 2026Option exercise41,669 shares · $0
    Avg. price $0604,161 shares held after
  • Puri Raj K.Chief Regulatory Officer · Sep 1, 2026Option exercise5,470 shares · $0
    Avg. price $0253,584 shares held after
  • Kirby Daniel GordonChief Commercial Officer · Aug 10, 2026Shares withheld for taxes2,436 shares · $16K
    Avg. price $6.4154,511 shares held after
  • Kirby Daniel GordonChief Commercial Officer · Aug 10, 2026Option exercise10,001 shares · $0
    Avg. price $0156,947 shares held after
  • Roche Corleen M.Chief Financial Officer · Aug 6, 2026Shares withheld for taxes21,238 shares · $132K
    Avg. price $6.2128,757 shares held after
  • Roche Corleen M.Chief Financial Officer · Aug 6, 2026Option exercise49,995 shares · $0
    Avg. price $049,995 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Iovance Biotherapeutics (IOVA) stock information

NASDAQ

Iovance Biotherapeutics (IOVA) is listed on NASDAQ. Its market capitalization is about $3.5B. On trailing-twelve-month earnings the P/E ratio is -15.85, and the P/B ratio is 4.29. Return on equity is -27.1%. These figures are computed in-house from official filings and are reference information only.

Iovance Biotherapeutics — frequently asked questions

What is the P/E ratio of Iovance Biotherapeutics (IOVA)?
On a trailing-twelve-month basis, IOVA trades at a P/E ratio of -15.85. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Iovance Biotherapeutics?
IOVA has a market capitalization of about $3.5B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.